Healthcare-associated infections (HAIs) are acquired while patients
receive treatment for another condition in a healthcare setting. The
Utah Department of Health and Human Services (DHHS) works with community
partners to monitor and prevent these infections because they are a
critical threat to patient safety and extremely costly to treat. Utah Health
Code Title 26B, Chapter 7, Section 221, Public Reporting of Healthcare
Associated Infections, requires the DHHS to collect data on HAIs
from healthcare facilities and report this data to the public on an
annual basis. This report contains the following data:
The information in this report has several limitations and should
be considered as an overview of HAIs in Utah. The data displayed comes
from NHSN which are self-reported by healthcare facilities.
Additionally, data are only included from facilities required by the CMS
to report to NHSN. CMS reporting requirements also vary for each
disease/condition depending on the facility type. Validation of these
data by DHHS is limited. Data does not reflect variabilities of patient
acuity experienced in different facility settings. The COVID-19 pandemic
may have impacted the data collection and HAI rates.
Utah Department of Health and Human Services
Healthcare-associated infections and antimicrobial resistance program
P.O. Box 142104
Salt Lake City, UT 84114
PH 801-538-6191
• FAX 801-538-9923
Healthcare-associated infections (HAIs) are a major, often
preventable, threat to patient safety. Thank you to all the healthcare
professionals and facilities in Utah who are committed to protecting
patients and healthcare personnel and tirelessly work toward the goal of
eliminating these preventable infections. The Utah Department of Health
and Human Services (DHHS) Healthcare-associated Infections and
Antimicrobial Resistance (HAI/AR) program helps Utah patients receive
the best and safest care. Implementation of statewide HAI prevention
efforts is an essential part of a comprehensive patient safety program.
Publicly released HAI data is an important step in transparency creation
for healthcare safety and quality in Utah.
Patients have a right to feel safe and assured that public health is
working to eliminate preventable infections. Two keys to HAI elimination
are 1) accurate data collection to assess prevention impact, and 2)
dissemination of results to healthcare providers and consumers.
Conscientious efforts in data reporting contribute toward meeting HAI
prevention efforts and control needs.
This 2022 Annual healthcare-associated infections report was
developed in accordance with recommendations established by the Utah
healthcare infection prevention governance committee (UHIP-GC), a
multi-disciplinary panel of state leaders in patient safety, infectious
diseases, and infection control. It provides an update on previous HAI
reports and details our progress toward the goal of reduction and,
ultimately, elimination of HAIs.
This report allows Utahns to compare HAIs among 5 healthcare settings (acute care hospitals, critical access hospitals, long-term acute care hospitals, inpatient rehabilitation facilities, and dialysis facilities) in Utah and the U.S. The data in this report are self-reported to the National Healthcare Safety Network (NHSN) by each facility required to report HAIs by the Centers for Medicare and Medicaid Services (CMS). The DHHS analyzes the data using proven statistical methods to provide comparison information.
Clinical Coordinator
HAI/AR Program
Utah Department
of Health and Human Services
We recommend reading through the light green tabs first, which include the executive summary, foreword, and interpreting HAI data. Then, click on the dark purple Utah HAIs tab above to see drop down data pages on each HAI. The last About the data tab goes through the introduction, how Utah HAI data is collected, data quality validation, validation conclusions, references, and acknowledgements.
In the Overview and events tables, column headers may be underlined with light blue. Hover over these to read term definitions.
Thank you!
The SIR is the ratio of the observed number of infections (events) to the number of predicted infections (events) for a specific time period.
National baseline: Aggregated data reported to the National Healthcare Safety Network (NHSN) by all facilities during a baseline period is used to “predict” the number of infections expected to occur in a hospital, state, or in the country. In the 2022 National and State Healthcare-Associated Infections (HAI) Progress Report, the number of predicted infections is an estimate adjusted for each facility through the use of variables known to be significant predictors of HAIs, such as the number of community-onset infections or the number of annual patient days. Incidence was also analyzed for each quarter in 2021 and compared with 2022, with appropriate risk adjustments made for the respective HAI, to assess the impact of COVID-19 on HAIs. Due to the high number of hospitalizations in 2020, the predicted number of infections was significantly higher than previous years for most HAIs.
SIR value | Interpretation |
---|---|
Fewer than 1 | There were fewer infections observed than predicted, based on the national aggregate data. |
Equal to 1 | There were about the same number of infections observed as predicted, based on the national aggregate data. |
More than 1 | There were more infections observed than predicted, based on the national aggregate data. |
Examples: 45 observed cases/30 expected cases:
the SIR is 45/30 = 1.5 Since 1.5 is 50% greater than 1, the SIR
indicated an excess of 50%.
15 observed cases/30 expected cases: the SIR is 15/30 = 0.5 Since 0.5
is 50% less than 1, a SIR = 0.5 would indicate a 50% decrease.
To enforce a minimum precision criterion, SIRs are only calculated when
the number of predicted infections is greater than 1. This rule was
instituted by NHSN to avoid the calculation and interpretation of
statistically imprecise SIRs, which typically have extreme values.
Key:
Statistically FEWER infections than the national
aggregate data
Statistically
MORE infections than the national aggregate data
Predicted to have less than one infection for the year, and had
ZERO infections, as defined by NHSN, in 2022
Predicted to have less than one infection for the year, but had one or
more infections, as defined by NHSN, in 2022
NOT statistically different from the national aggregate data
Utah SIRs compared to national aggregate data:
Healthcare-associated infections (HAIs) are infections people acquire
while they receive treatment for another condition in a healthcare
setting. HAIs can be acquired anywhere healthcare is delivered,
including inpatient acute care hospitals (ACH), outpatient settings
(ambulatory surgical centers and dialysis facilities), and long-term
care facilities (nursing homes and rehabilitation centers). HAIs may be
caused by any infectious agent, including bacteria, fungi, and viruses,
as well as other less common pathogens. HAIs include central-line
associated bloodstream infections (CLABSIs), catheter-associated urinary
tract infections (CAUTIs), surgical site infections (SSIs),
methicillin-resistant Staphylococcus aureus (MRSA) bacteremia
infections, and Clostridioides difficile-associated infections
(CDIs).
Economic studies estimate HAI treatments cost more than $9 billion a
year when looking from the hospital perspective (Scott et al., 2019).
However, this does not address the societal cost perspective. HAIs can
have devastating emotional, financial, and medical consequences for the
person affected (HHS, 2022). Each day, approximately 1 in 31 U.S.
hospitalized patients has at least 1 infection associated with their
care. These infections can lead to significant morbidity and mortality,
with tens of thousands of lives lost each year, which underscores the
need for improvements in infection prevention practices in U.S.
healthcare facilities (Agency for Healthcare Research and Quality
[AHRQ], 2019; CDC, 2018).
The DHHS HAI/AR program’s mission is to prevent healthcare-associated infections and the spread of antimicrobial-resistant organisms through collaboration with partners; surveillance and response to outbreaks; data analysis; education; and policy change. The program produces this annual report to document and analyze HAI trends in Utah healthcare facilities (reporting facilities are outlined in the executive summary) as one of the activities under this mission. The NHSN statistics calculator was used to determine statistical significance. This calculator provides a relative ratio of SIRs, a two-tailed p-value, and a 95% confidence interval.
HAIs may be caused by various types of invasive devices, such as a
central line or urinary catheter, used when patients are ill (Marschall
et al., 2014). The longer these devices are in place, the greater the
risk for infection (U.S. Department of Health and Human Services [HHS],
2022). In 2022, U.S. acute care facilities observed decreases in annual
HAI rates for CLABSIs and CAUTIs when compared with 2021. Specifically,
acute care facilities reported a 9% decrease in CLABSIs and a 12%
decrease in CAUTIs (Centers for Disease Control and Prevention [CDC],
2023). In Utah, decreases were also observed for both CLABSIs and CAUTIs
(7% and 4%, respectively). However, the SIRs were not found to be
significantly different when compared with 2021 (p=0.57 and p=0.78,
respectively) (CDC National Healthcare Safety Network [NHSN], 2023a).
HAIs may also occur as a result of complications following a surgical
procedure or when infection control practices such as hand washing are
not followed (Anderson et al., 2014). While advances have been made in
infection control and prevention and antimicrobial prophylaxis, these
infections are not uncommon and account for 20% of all HAIs nationwide
(CDC NHSN, 2023b). According to the 2022 National and State
Healthcare-Associated Infections Progress Report, there were no
significant changes in abdominal hysterectomy SSIs at the national level
(CDC, 2023). Utah experienced an increase that was not found to be
statistically significant when compared with Utah’s 2021 SIR (p= 0.39).
The increase was due to only 2 additional events. The infection rates
for colon surgery SSIs had no statistically significant change from 2021
for both Utah and the U.S. (CDC 2023; CDC NHSN, 2023a).
MRSA is a bacterium resistant to many antibiotics and is common in
healthcare facilities. In the community, most MRSA infections are skin
infections. In medical facilities, MRSA may cause life-threatening
bloodstream (or bacteremia) infections, endocarditis, pneumonia, and
surgical site infections (Calfee et al., 2014). Although significant
progress has been made to reduce MRSA bloodstream infections, MRSA still
poses a formidable clinical threat, with persistently high morbidity and
mortality (Turner et al., 2019). The total number of MRSA bacteremia
cases reported both nationally and in Utah decreased from 2021 to 2022.
U.S. acute care facilities experienced a 16% decrease (CDC, 2023), and
Utah experienced a 32% decrease when comparing SIRs from 2021 and 2022.
Though the national decrease was found to be statistically different,
the decrease in Utah was not found to be significant (p= 0.08). However,
it is worth noting that 35 acute care facilities in Utah reported 0
cases of MRSA in 2022 (CDC NHSN, 2023a).
Patients who receive medical care and take antibiotics for long
periods of time are more susceptible to HAIs, such as CDIs. Although
antibiotics quickly and effectively eliminate bacterial infections, they
also get rid of the good bacteria that protects the body against harmful
infections. Antibiotic misuse and subsequent antibiotic resistance has
driven the growth of CDIs and the emergence of new strains (Spigaglia,
2016). CDIs are estimated to cause almost half a million infections in
the U.S. each year, and now rival MRSA as the most common organism to
cause HAIs in the U.S. (CDC 2022b; Dubberke et al., 2014). Furthermore,
one in 11 patients older than age 65 with CDI die within a month of
diagnosis (CDC, 2022b). Fortunately, there was a 3% decrease in hospital
onset CDIs in the U.S. ACHs between 2021 and 2022 (CDC, 2023). Utah
experienced a 2% increase; however, the difference in SIRs was not found
to be statistically significant (p= 0.83) (CDC NHSN, 2023a).
Patients who undergo dialysis treatment (a treatment for patients who
have inadequate kidney function) also have an increased risk for
acquiring HAIs. They are at high risk because this artificial process to
get rid of waste and fluid in the body requires frequent use of
catheters to access the bloodstream. Dialysis patients may have weakened
immune systems, which also increases their risk for infection (CDC,
2020). The SIR of dialysis event bloodstream infections (BSI) has
continued to decrease each year both nationally and in Utah. Although
this report shows a larger overall number of events than 2021, the SIR
has decreased. A comparison of Utah dialysis BSI event SIRs from 2021 to
2022 shows a 23% decrease. This difference was not found to be
statistically significant (p= 0.21) (CDC NHSN, 2023). The larger number
of events in 2022 is not a true increase and is likely due to the DHHS
HAI/AR program staff assisting 13 facilities in sharing their NHSN data
to the state of Utah. This is an important step for data accuracy in
this annual report as well as guiding where to implement targeted
infection prevention efforts within the state.
The impacts to HAI incidence were particularly evident during the COVID-19 pandemic. Not only were there challenges in the healthcare response to rising hospitalization rates, there were also documented shortages in healthcare personnel, which led to decreased HAI prevention and surveillance by facilities (Wu et al., 2021). The nation continued to experience unprecedented challenges due to the COVID-19 pandemic in 2021; however, hospitals resumed mandated reporting of HAIs which resulted in a return to pre-pandemic numbers of facilities reporting into NHSN. CDC analysis reveals that many HAIs continued to increase in U.S. hospitals during 2021, the second year of the COVID-19 pandemic. Most notably, NHSN data shows a significantly higher incidence in central line-associated bloodstream infections (CLABSIs), catheter-associated urinary tract infections (CAUTIs), and methicillin-resistant Staphylococcus aureus (MRSA) bacteremia in 2021 compared with 2019 (CDC, 2022a). 2022 marks a return to a more normal state with hospitals resuming required reporting. The increased incidence observed for certain diseases/conditions did not continue in 2022.
These findings stress the importance of action from public health and
healthcare facilities to eliminate infections that commonly threaten
hospital patients, especially during times of emergent crises.
Identification of healthcare-associated infections (HAIs) requires an
organized, multi-pronged approach. It is important to determine whether
infections are healthcare-associated or already present upon facility
admission. State
regulations require the Utah Department of Health and Human Services
(DHHS) to collect and report data on HAIs because of the concern about
how deadly and costly HAIs are.
Acute care hospitals with intensive care units have submitted data
directly to the DHHS for the annual HAI report since 2008. However,
reporting facilities were not identified by name. In 2011, the Centers
for Medicare and Medicaid Services (CMS) required acute healthcare
facilities to report specific HAI data to the National Healthcare Safety
Network (NHSN) for payment reimbursement. In 2012, Utah Health
Code Title 26B, Chapter 7, Section 221, Public Reporting of Healthcare
Associated Infections, was passed which requires the DHHS to: a)
access and analyze facility-specific NHSN data required by CMS; b)
publish an annual HAI report for the public in which facilities are
identified by name; and c) conduct validation activities.
Facilities in Utah submit data about specific HAIs to the NHSN, a
secure, online tracking system used by hospitals and other healthcare
facilities. The Utah data are reported to NHSN by each facility that is
required to report HAIs to CMS. More than 38,000 hospitals and other
healthcare facilities nationwide report data to NHSN. This information
is then used to summarize HAI data at the national level and for care
improvement by facilities, states, regions, quality groups, and national
public health agencies, including the Centers for Disease Control and
Prevention (CDC).
For an HAI to be publicly reported in Utah under Title 26B, Chapter 7, Section 221, an HAI must meet CMS’s specific reporting measures required for reporting to NHSN. The DHHS works with NHSN and other partners to monitor and prevent these infections as they are a significant threat to patient safety.
The Department of Health and Human Services (DHHS) is required under
Utah Title 26B-7-221, Public Reporting of Healthcare-Associated
Infections (HAIs), to validate data reported to the National Healthcare
Safety Network (NHSN). Guidance from the Centers for Disease Control and
Prevention (CDC) helped direct the selection of infection types for
validation of 2022 NHSN data. This guidance included the use of results
from the targeted assessment for prevention (TAP) strategy to prioritize
activities and focus on acute care hospitals (ACH). This information led
DHHS to perform validation of central-line associated bloodstream
infections (CLABSIs) and catheter-associated urinary tract infections
(CAUTIs) events.
The focus of these validation activities was to determine how NHSN
CLABSI and CAUTI event surveillance definitions were interpreted and
applied to data collection. The validations were performed by the DHHS
HAI/AR program at healthcare facilities throughout the state. Facilities
were chosen based on an NHSN random selection process from the NHSN
External Validation Guidance and Toolkit for 2022. This selection
process is designed to prioritize measurement of a representative sample
of facilities to produce an estimate of the inter-rater reliability of
the HAI event determination.
Validation activities are intended to compare reported information in
NHSN with DHHS audit findings and outcomes to enhance accuracy and
completeness of CLABSI and CAUTI reporting. A standardized validation
method, as guided by NHSN, was chosen to serve as a test of proficiency
in surveillance methods and accuracy in case findings. It should also be
noted that results from these facilities may not be generalized to all
facilities in the state. Aggregate findings are not necessarily
indicative of NHSN data quality throughout the state.
An on-site medical record audit was conducted at the chosen healthcare facilities (2 ACHs). Each visit started with an interview of at least 1 member of the infection prevention staff to learn about surveillance methodology, data collection, and personnel training and education on applications of NHSN criteria. The assessment team used CDC’s targeted assessment for prevention (TAP) tools at each facility to determine current prevention practices and make recommendations based on those responses. As many as 10 charts were reviewed in each facility, including charts of patients identified by the facility as having a CLABSI event and charts of patients who had a positive blood culture but were not identified as having a CLABSI. The goal was to determine if any reportable infections were missed. Team members also reviewed as many as 10 charts of patients who were determined to have a CAUTI in 2022 to determine if they correctly met the CAUTI criteria. They also reviewed as many as 10 charts of patients who had a positive urine culture (a urine culture with no more than 2 species of organisms identified, at least 1 of which is a bacterium with >10 ^5 CFU/mL), but were not classified as a CAUTI, to determine if any reportable infections were missed. Results of the validation findings were reviewed with the facility to provide immediate on-site education to improve HAI surveillance and reporting. No errors in reporting CLABSIs or CAUTIs were identified.
Infection preventionists at the validated facilities (acute care
hospitals [ACHs]) correctly determined which patients met the
central-line associated bloodstream infection (CLABSI) definition and
applied the definition appropriately. Factors such as the timeline of
central line placement, blood culture results, symptom history, and the
type of organism identified must all be considered to determine whether
CLABSI criteria were met. For complete CLABSI definitions, refer to the
National
Healthcare Safety Network (NHSN) laboratory confirmed bloodstream
infection (LCBI) Checklist.
All infection preventionists at the validated facilities (ACHs)
correctly determined which patients met the catheter-associated urinary
tract infections (CAUTI) definition and applied the definition
appropriately. When performing CAUTI validation, the criteria used to
meet the definition included: a urine culture with no more than 2
species of organism identified, at least 1 of which is a bacterium with
> 10 (5) CFU/ml; an indwelling urinary catheter which had been in
place for longer than 2 consecutive days on the day of the event; and
the indicative signs and symptoms were present at the appropriate time
during the infection window period. If no signs or symptoms were present
but all other criteria were met, then a blood specimen with at least 1
matching bacterium to the bacterium in the urine specimen could be used
to meet criteria for a CAUTI.
The Centers for Disease Control and Prevention (CDC) targeted
assessment for prevention (TAP) facility assessment was administered to
7 different ACHs with 23 respondents who worked as nurses or in nurse
leadership. CDC TAP facility assessment tools for CAUTIs in ACHs
demonstrated that 100% of all respondents from facilities reported
leadership who actively promoted CAUTI prevention activities.
Furthermore, all facilities reported they provide training to the
appropriate healthcare personnel on each of the proper treatment
practices addressed in the assessment. However, conducting regular
competency assessments for each of these practices highlights an area
for improvement. For example, all respondents from facilities reported
conducting competency assessments on aseptic technique for urinary
catheter insertion upon hire; however, only 70% reported assessing this
at least annually. Additionally, 68% of respondents from facilities
reported conducting annual assessments on proper urinary catheter
maintenance procedures, and only 43% reported conducting annual
assessments on the use of bladder scanners. Regarding appropriate urine
culturing practices, 73% of respondents reported that ordering providers
often or always send urine cultures only on patients with signs or
symptoms of a urinary tract infection. In contrast, 18% of respondents
reported that ordering providers practice this sometimes, and 9% of
respondents were unsure.
Validation results show that facilities which were validated have a
good understanding of reporting criteria and report
healthcare-associated infections (HAIs) accurately into NHSN. However,
local surveillance data quality, HAI surveillance data completeness,
timeliness, sensitivity, and specificity can always be improved.
Additionally, as standardized infection ratios (SIR) remain above the
national target outlined in the HHS National Action Plan to Prevent
Healthcare-Associated Infections, there is a continued need for robust
validation programs (HHS, 2022). It is important to determine whether
infections are healthcare-associated or were already present upon
facility admission in order to implement appropriate infection
prevention measures. Accurate HAI data supports facilities’ efforts to
implement effective infection prevention strategies. The validation site
visit provides an opportunity for collaboration and education. The
HAI/AR program extends our appreciation to the facilities chosen for
validation visits.
The DHHS HAI/AR program staff provided technical support, education,
and data correction assistance to healthcare facilities reporting to
NHSN. In 2022, this included a focus on work with acute care and
dialysis facilities. The team helped 13 dialysis facilities share their
NHSN data to the state of Utah. This is important for data accuracy in
the annual HAI report as well as targeted infection prevention efforts
within the state.
The lessons learned from validation visits are discussed below. Additional validation visits took place during the 2023 calendar year using 2021 data that are not included in this report. However, these visits helped inform the lessons learned.
-Some infection preventionists counted patients with central lines in their denominator counts only if the central line had been accessed. However, all patients with at least one central line in place at the time of the count are included in the denominator regardless of access or the number of days the central line was in place. This differs from establishing whether a bloodstream infection is central line-associated when the count to determining whether a central line is eligible for CLABSI events begins on the day it is first accessed in an inpatient location during the current admission.
-One facility correctly attributed a bloodstream infection as secondary to a pneumonia infection. The patient met the PNU1 definition following admission to the facility. A blood specimen positive for MRSA was collected outside of the PNU1 infection window period (IWP), but during the repeat infection time period (RIT). During the RIT, all the necessary elements to satisfy the PNU2 definition were present in a separate IWP using the blood specimen positive for MRSA. This meets Scenario 2 for attributing bloodstream infections as secondary in which the organism in the blood specimen is an element used to meet the NHSN site-specific infection criterion. Q10 of CDC’s FAQs: Pneumonia (PNEU) Events highlights this exact scenario that was observed for this facility and is a great resource for further information.
AHRQ Agency for Healthcare Research and Quality. Estimating the additional hospital inpatient cost and mortality associated with selected hospital-Acquired conditions. (2017, November). Retrieved from https://www.ahrq.gov/hai/pfp/haccost2017-results.html
AHRQ Agency for Healthcare Research and Quality Patient Safety Network. Patient Safety 101. Health Care - Associated Infections. (2019, September 7). Retrieved from https://psnet.ahrq.gov/primer/health-care-associated-infections
Anderson, D. J., Podgorny, K., Berríos-Torres, S. I., Bratzler, D. W., Dellinger, E. P., Greene, L., Nyquist, A.-C., Saiman, L., Yokoe, D. S., Maragakis, L. L., & Kaye, K. S. (2014). Strategies to prevent surgical site infections in acute care hospitals: 2014 update. Infection Control and Hospital Epidemiology, 35(6), 605–627. https://doi.org/10.1086/676022
Calfee, D. P., Salgado, C. D., Milstone, A. M., Harris, A. D., Kuhar, D. T., Moody, J., Aureden, K., Huang, S. S., Maragakis, L. L., & Yokoe, D. S. (2014). Strategies to prevent Methicillin-Resistant Staphylococcus aureus transmission and infection in acute care hospitals: 2014 update. Infection Control and Hospital Epidemiology, 35(7), 772–796. https://doi.org/10.1086/676534
Centers for Disease Control and Prevention. (2012, March 6). Making health care safer - Stopping C. difficile infections. Retrieved from https://www.cdc.gov/vitalsigns/pdf/2012-03-vitalsigns.pdf
Centers for Disease Control and Prevention. (2015, October 16). Catheter-Associated urinary tract infections (CAUTI). Retrieved from https://www.cdc.gov/hai/ca_uti/uti.html
Centers for Disease Control and Prevention. (2018, October 5). Healthcare associated infections (HAIs): HAI data. Retrieved from https://www.cdc.gov/hai/data/index.html
Centers for Disease Control and Prevention. (2019, December). Antibiotic resistance threats 2019. Retrieved from https://www.cdc.gov/drugresistance/pdf/threats-report/2019-ar-threats-report-508.pdf
Centers for Disease Control and Prevention. (2020, January 7). Dialysis safety. Retrieved from https://www.cdc.gov/dialysis/
Centers for Disease Control and Prevention. (2022a, November 4). 2021 National and state healthcare-Associated infections progress report. Retrieved from https://www.cdc.gov/hai/data/archive/2021-HAI-progress-report.html
Centers for Disease Control and Prevention. (2022b, September 7). C. diff (Clostridioides difficile). Retrieved from https://www.cdc.gov/cdiff/index.html
Centers for Disease Control and Prevention. (2023, December 1). 2022 National and State Healthcare-Associated Infections Progress Report. Retrieved from https://www.cdc.gov/hai/data/portal/progress-report.html
CDC National Healthcare Safety Network (NHSN). (2023a). Patient safety component. Retrieved from http://www.cdc.gov/nhsn/
CDC National Healthcare Safety Network (NHSN). (2023b). Surgical site infection event (SSI). Retrieved from https://www.cdc.gov/nhsn/pdfs/pscmanual/9pscssicurrent.pdf
Dubberke, E. R., Carling, P., Carrico, R., Donskey, C. J., Loo, V. G., McDonald, L. C., Maragakis, L. L., Sandora, T. J., Weber, D. J., Yokoe, D. S., & Gerding, D. N. (2014). Strategies to prevent Clostridium difficile infections in acute care hospitals: 2014 update. Infection Control and Hospital Epidemiology, 35(6), 628–645. https://doi.org/10.1086/676023
Marschall, J., Mermel, L. A., Fakih, M., Hadaway, L., Kallen, A., O’Grady, N. P., Pettis, A. M., Rupp, M. E., Sandora, T., Maragakis, L. L., & Yokoe, D. S. (2014). Strategies to prevent central line–Associated bloodstream infections in acute care hospitals: 2014 update. Infection Control and Hospital Epidemiology, 35(7), 753–771. https://doi.org/10.1086/676533
Moriyama, K., Ando, T., Kotani, M., Tokumine, J., Nakazawa, H., Motoyasu, A., Yorozu, T., (2022). Risk factors associated with increased incidences of catheter-related bloodstream infection. Medicine 101(42):p e31160, October 21, 2022. https://doi.org/10.1097/MD.0000000000031160
Scott, R. D., Culler, S. D., Rask, K. J., (2019). Understanding the economic impact of health care-associated infections: A cost perspective analysis. The Art and Science of Infusion Nursing, 42(2), 61-69. https://doi.org/10.1097/NAN.0000000000000313
Spigaglia P. (2016). Recent advances in the understanding of antibiotic resistance in Clostridium difficile infection. Therapeutic advances in infectious disease, 3(1), 23–42. https://doi.org/10.1177/2049936115622891
Turner, N.A., Sharma-Kuinkel, B. K., Maskarinec, S. A., Eichenberger, E. M., Shah, P. P., Carugati, M., Holland, T. L., Fowler, V. G. (2019). Methicillin-Resistant Staphylococcus aureus: an overview of basic and clinical research. Nature Reviews Microbiology, 17, 203–218 (2019). https://doi.org/10.1038/s41579-018-0147-4
U.S. Department of Health & Human Services. (2022, December 7). National action plan to prevent health care associated infections: Road map to elimination. Retrieved from https://www.hhs.gov/oidp/topics/health-care-associated-infections/hai-action-plan/index.html
Wu, H., Soe, M. M., Konnor, R., Dantes, R., Haass, K., Dudeck, M. A., Gross, C., Leaptrot, D., Sapiano, M. R. P., Allen-Bridson, K., Wattenmaker, L., Peterson, K., Lemoine, K., Chernetsky Tejedor, S., Edwards, J. R., Pollock, D., Benin, A. L., & National Healthcare Safety Network (2022). Hospital capacities and shortages of healthcare resources among US hospitals during the coronavirus disease 2019 (COVID-19) pandemic, National Healthcare Safety Network (NHSN), March 27-July 14, 2020. Infection control and hospital epidemiology, 43(10), 1473–1476. https://doi.org/10.1017/ice.2021.280
Prepared by:
Devin Beard, Jacob Anderson,
Charisse Schenk, Ashley Young, April Clements
Division of Population
Health
Healthcare-associated infections and
antimicrobial resistance program
Utah Department of Health and Human
Services
Special thanks to the following individuals for their subject matter
expertise, data resources, editing, and consultations:
Alex Coombs, BSN, RN, CIC | Danene Price, BSN, RN |
Angela Weil, APRN/MSN, CIC | Devin Beard, MPH |
April Clements, BSN, RN, CIC | Giulia De Vettori, MPH, CPH |
Ashley Young, MAS, CHES | Janelle Kammerman, BS |
Bea Jensen, BSN, RN, CIC | Jacob Anderson, MPH |
Charisse Schenk, MPH, CPH, CHES | Jonny Griffith, RN |
Chrissy Radloff, MS, RN, CIC | Linda Rider, BSN, RN, CIC |
Chief executive officers
Infection preventionists
Chief medical officers
Chief nursing officers
Quality improvement directors